蛋白琥珀酸铁口服液预防早产儿贫血的临床疗效观察

Clinical Study of Iron Proteinsuccinylate Oral Solutions for Preventing Anemia in Prematurity

目的:探讨蛋白琥珀酸铁口服液预防早产儿贫血的效果及其耐受性,为预防早产儿贫血的铁剂选择提供参考依据。方法:选取本院就诊的82例母乳喂养早产儿作为干预对象,随机分为蛋白琥珀酸铁组和右旋糖酐铁组,各41例。早产儿出生后2-4周口服铁剂1.5 mg·kg^-1·d^-1,于出生后6月龄检测血常规并记录与治疗相关的胃肠道不良反应发生情况。结果:蛋白琥珀酸铁组与右旋糖酐铁组的血红蛋白平均值无显著差别(P>0.05),在胃肠道不良反应方面,前者发生率低于后者(P=0.037)。结论:两种补铁剂在预防早产儿贫血方面疗效相当,但蛋白琥珀酸铁有更好的耐受性。

Objective:To investigate the effect and tolerance of iron proteinsuccinylate oral solutions for preventing anemia in premature infants,and to provide reference for the selection of iron agents for preventing premature anemia.Methods:Eighty-two premature infants who were breastfed in the high-risk pediatric management department of Huai'an Maternal and Child Health Hospital were selected and randomly divided into iron proteinsuccinate group and iron dextran group.The premature infants orally administered iron 1.5 mg·(kg·d)^-1 at 2-4 weeks after birth.Blood routine examinations were performed at 6 months after birth and the occurrence of treatment-related gastrointestinal adverse drug reactions were recorded.Results:There was no significant difference in the mean value of hemoglobin between the iron proteinsuccinate group and the iron dextran group(P>0.05);in terms of gastrointestinal adverse reactions,the incidence of the iron proteinsuccinate group was lower than that of the iron dextran group(P=0.037).Conclusion:Iron proteinsuccinylate oral solutions are comparable to iron dextran oral solutions in preventing anemia in prematurity with better tolerance.